AnaMar Announces Positive Phase I Data for its Phase II Ready Compound AM1476 for Treating Fibrosis
23 mai 2023 03h00 HE | AnaMar AB
First-in-class, peripheral serotonin (5-HT2B) receptor antagonist being developed as a highly selective, oral, anti-fibrotic medicine for skin and lung disorders LUND, Sweden, May 23, 2023 (GLOBE...
Human Genome Sciences and GlaxoSmithKline Announce Positive Results in Second of Two Phase 3 Trials of BENLYSTA(TM) in Systemic Lupus Erythematosus
02 nov. 2009 00h01 HE | Human Genome Sciences
ROCKVILLE, MD and LONDON--(Marketwire - November 2, 2009) - Human Genome Sciences, Inc. (NASDAQ: HGSI) and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA™ (belimumab) met the primary...